Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype'. The following are the other relevant details related to the trial:
Therapeutic Area: Respiratory
Trial Centre(s):
Changi General Hospital
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Anthony Yii Chau Ang
Dr Ng Shuen Kai Jeffrey
Dr Tiew Pei Yee
Dr Xu Huiying
Published by HT Digital...